SCHEMBL771326

SCHEMBL771326

O=C(c1ccccc1-c1cc2ccccc2[nH]1)n1ccnc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 4/20 0.43
AURKA O14965 1/20 0.43
CHEK1 O14757 1/20 0.43
SLC22A12 Q96S37 1/20 0.42
KDM4E B2RXH2 2/20 0.40
MEN1 O00255 2/20 0.40
ALDH1A1 P00352 2/20 0.40
MAPT P10636 2/20 0.40
HPGD P15428 2/20 0.40
KMT2A Q03164 2/20 0.40
RAB9A P51151 2/20 0.40
CYP19A1 P11511 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
USP2 O75604 1/20 0.39
LMNA P02545 1/20 0.39
POLB P06746 1/20 0.39
GAA P10253 1/20 0.39
ALOX15 P16050 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6396188 0.80 FLT3 (0.54) KDM4EALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL30366356 0.75 FAAH (0.44) KDM4EALDH1A1MAPTCYP19A1NPSR1
SCHEMBL27437769 0.74 KDR (0.56) KDRAURKACHEK1SLC22A12KDM4E
SCHEMBL28906323 0.73 KDR (0.54) KDRAURKACHEK1SLC22A12KDM4E
SCHEMBL31310116 0.73 KDR (0.54) KDRAURKACHEK1KDM4EMEN1
SCHEMBL11365957 0.73 KDR (0.54) KDRAURKACHEK1SLC22A12KDM4E
SCHEMBL2860216 0.73 KDR (0.54) KDRAURKACHEK1KDM4EMEN1
SCHEMBL10118094 0.72 ALDH1A1 (0.54) KDM4EALDH1A1KMT2ALMNAPOLB
SCHEMBL4623053 0.71 ESR1 (0.53) KDRAURKACHEK1SLC22A12KDM4E
SCHEMBL7062756 0.70 SLC22A12 (0.57) KDRAURKACHEK1SLC22A12KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-06-12 US disclosed
US-12187720-B2 Compounds for treatment of cancer UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-01-07 US disclosed
US-11465987-B2 Compounds for treatment of cancer Oncternal Therapeutics, Inc. (US) 2022-10-11 US disclosed
US-20220024912-A1 COMPOUNDS FOR TREATMENT OF CANCER Oncternal Therapeutics, Inc. (US) 2022-01-27 US disclosed
US-11084811-B2 Compounds for treatment of cancer Oncternal Therapeutics, Inc. (US) 2021-08-10 US disclosed
US-10865196-B2 Compounds for treatment of cancer UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2020-12-15 US disclosed
US-10301285-B2 Compounds for treatment of cancer GTX, INC. (US) 2019-05-28 US disclosed
US-20190092755-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2019-03-28 US disclosed
US-20180093971-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2018-04-05 US disclosed
US-20170226086-A1 COMPOUNDS FOR TREATMENT OF CANCER GTx. Inc. (US) 2017-08-10 US disclosed
US-9447049-B2 Compounds for treatment of cancer UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2016-09-20 US disclosed
US-9334242-B2 Compounds for treatment of cancer GTX, INC. (US) 2016-05-10 US disclosed
US-9029408-B2 Compounds for treatment of cancer GTX, INC. (US) 2015-05-12 US disclosed
US-8822513-B2 Compounds for treatment of cancer GTX, INC. (US) 2014-09-02 US disclosed
US-20140213623-A1 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2014-07-31 US disclosed
US-20130197049-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2013-08-01 US disclosed
US-20120071524-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2012-03-22 US disclosed
US-20110257196-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2011-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187720-B2 Compounds for treatment of cancer KLK3, BRDT, ACP3 KDR 2787/4885AURKA 255/4885CHEK1 160/4885
US-20120071524-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 KDR 2787/4885AURKA 255/4885CHEK1 160/4885
US-10865196-B2 Compounds for treatment of cancer CYP19A1, CYP17A1, SOX18 KDR 4147/4885AURKA 495/4885CHEK1 895/4885
US-10301285-B2 Compounds for treatment of cancer CYP19A1, CYP17A1, SOX18 KDR 4147/4885AURKA 495/4885CHEK1 895/4885
US-20130197049-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 KDR 2787/4885AURKA 255/4885CHEK1 160/4885
US-20140213623-A1 COMPOUNDS FOR TREATMENT OF CANCER CYP19A1, CYP17A1, SOX18 KDR 4147/4885AURKA 495/4885CHEK1 895/4885
US-20180093971-A1 COMPOUNDS FOR TREATMENT OF CANCER CYP19A1, CYP17A1, SOX18 KDR 4147/4885AURKA 495/4885CHEK1 895/4885
US-11084811-B2 Compounds for treatment of cancer KLK3, BRDT, ACP3 KDR 2787/4885AURKA 255/4885CHEK1 160/4885
US-20220024912-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 KDR 2787/4885AURKA 255/4885CHEK1 160/4885
US-20170226086-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 KDR 2787/4885AURKA 255/4885CHEK1 160/4885
US-20110257196-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 KDR 2787/4885AURKA 255/4885CHEK1 160/4885
US-20190092755-A1 COMPOUNDS FOR TREATMENT OF CANCER CYP19A1, CYP17A1, SOX18 KDR 4147/4885AURKA 495/4885CHEK1 895/4885
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 KDR 2787/4885AURKA 255/4885CHEK1 160/4885
US-11465987-B2 Compounds for treatment of cancer KLK3, BRDT, ACP3 KDR 2787/4885AURKA 255/4885CHEK1 160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.